You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial
|
|---|---|
| Published in |
Lancet Oncology, November 2012
|
| DOI | 10.1016/s1470-2045(12)70423-0 |
| Pubmed ID | |
| Authors |
James W Denham, Chantelle Wilcox, David Joseph, Nigel A Spry, David S Lamb, Keen-Hun Tai, John Matthews, Chris Atkinson, Sandra Turner, David Christie, Nirdosh Kumar Gogna, Lizbeth Kenny, Gillian Duchesne, Brett Delahunt, Patrick McElduff |
| Abstract |
Adjuvant androgen suppression and bisphosphonates with escalating doses of radiotherapy might improve efficacy outcomes in men with locally advanced prostate cancer. In this study, we investigated whether these treatments had a detrimental effect on patient-reported-outcome (PRO) scores. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 60% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 2 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | <1% |
| China | 1 | <1% |
| Unknown | 116 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 21 | 18% |
| Researcher | 14 | 12% |
| Student > Ph. D. Student | 11 | 9% |
| Student > Doctoral Student | 11 | 9% |
| Other | 9 | 8% |
| Other | 29 | 25% |
| Unknown | 23 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 44% |
| Nursing and Health Professions | 8 | 7% |
| Psychology | 5 | 4% |
| Agricultural and Biological Sciences | 4 | 3% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 15 | 13% |
| Unknown | 31 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2019.
All research outputs
#6,389,780
of 25,728,855 outputs
Outputs from Lancet Oncology
#3,676
of 6,937 outputs
Outputs of similar age
#45,415
of 194,063 outputs
Outputs of similar age from Lancet Oncology
#38
of 109 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,937 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.8. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,063 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 109 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.